Spain has begun using a new genetic ALS therapy that targets the SOD1 mutation and may slow nerve damage in patients with this rare condition.

CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (BIIB) (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous ...

NANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy ...

Eight years after receiving a life-shattering diagnosis, a New Jersey mother credits an “amazing” new drug for stopping her disease in its tracks. Raziel Green, 52, an active runner and mother of two, ...

Please provide your email address to receive an email when new articles are posted on . The European Commission has granted marketing authorization under exceptional circumstances for Qalsody to treat ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Neurofilament light chain and cerebrospinal fluid ...

Rickey Malloy (left), who receives tofersen treatment for SOD1-ALS at WashU Medicine, plays a round of golf with his wife, Jenny, and their son, Kash. Long-term use of tofersen, a new drug approved by ...

uniQure N.V. announced that its Independent Data Monitoring Committee (IDMC) has reviewed the safety data from the first cohort of its Phase I/II clinical trial for AMT-162, a gene therapy aimed at ...